Published in Healthcare Mergers, Acquisitions and Ventures Week, February 24th, 2007
"We are convinced that innovations in molecular imaging have the potential to fundamentally improve the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease. Bayer Schering Pharma is already pursuing the development of tracers targeting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week